



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 000 622 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:  
17.05.2000 Bulletin 2000/20

(51) Int. Cl.<sup>7</sup>: A61K 31/52

(21) Application number: 99120803.4

(22) Date of filing: 21.10.1999

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE  
Designated Extension States:  
AL LT LV MK RO SI

(30) Priority: 30.10.1998 JP 30928498

(71) Applicant: Fujirebio Inc.  
Tokyo (JP)

(72) Inventors:  
- Hirasawa, Keisuke  
Chuo-ku, Tokyo (JP)  
- Fujinami, Takako  
Chuo-ku, Tokyo (JP)  
- Yoshida, Osamu  
Chuo-ku, Tokyo (JP)

(74) Representative: HOFFMANN - EITLE  
Patent- und Rechtsanwälte  
Arabellastrasse 4  
81925 München (DE)

(54) Antiviral agents

(57) The present invention discloses an antiviral agent containing as an active ingredient one or more compounds selected from the group consisting of adenine, hypoxanthine, guanine, their water-soluble derivatives and their prodrugs. The antiviral agent can demonstrate efficacy by a mechanism which is different from that of conventional nucleoside reverse transcriptase inhibitors and protease inhibitors.

10/820,869

EP 1 000 622 A2

## Description

## Brief Description of the Drawings

## Technical Field to which the Invention Belongs

## [0007]

[0001] The present invention relates to a novel and useful antiviral agent, and more particularly, to an antiviral agent containing as an active ingredient a compound or compounds selected from the group consisting of adenine, hypoxanthine, guanine, their water-soluble derivatives and their prodrugs.

5

Fig. 1 shows the effect of adenine on the selective induction of apoptosis to virus-infected cells.  
 Fig. 2 shows the effect of GDP on the selective induction of apoptosis to virus-infected cells.  
 Fig. 3 shows the effect of inosine on the selective induction of apoptosis to virus-infected cells.  
 Fig. 4 shows DNA fragmentation in Molt-4/HIV cells by selective apoptosis-inducing substances.

10

## Related Background Art

## Description of the Preferred Embodiments

15

[0002] As antiviral agents for treating individuals (living organisms) infected with type A, type B or type C hepatitis virus or immunodeficiency virus (HIV) that causes the onset of AIDS, nucleoside reverse transcriptase inhibitors represented by zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), lamivudine (3TC), stavudine (d4T) and the like, and protease inhibitors represented by indinavir, saquinavir, ritonavir and the like have been known when anti-HIV agents are taken as an example.

20

[0003] In the case of conventional antiviral agents, when individual compounds are administered alone, resistant strains appear easily, based on mutation of virus and then therapeutic efficacy is readily lost. Thus the improvement of the therapeutic efficacy has been attempted with concomitant use of 2 or 3 agents. In the case of treatment by this concomitant use, the amount of virus in the blood is an undetectable level. The number of infected CD4+ cells does not expectedly increase. The termination of treatment causes rebound effects and virus levels again increase rapidly leading to exacerbation of symptoms. These agents thus do not serve as eradication therapeutic agents in actual situations and there are also similar problems observed to other viruses, and thus novel therapeutic agents have been needed.

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

105

110

115

120

125

130

135

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

225

230

235

240

245

250

255

260

265

270

275

280

285

290

295

300

305

310

315

320

325

330

335

340

345

350

355

360

365

370

375

380

385

390

395

400

405

410

415

420

425

430

435

440

445

450

455

460

465

470

475

480

485

490

495

500

505

510

515

520

525

530

535

540

545

550

555

560

565

570

575

580

585

590

595

600

605

610

615

620

625

630

635

640

645

650

655

660

665

670

675

680

685

690

695

700

705

710

715

720

725

730

735

740

745

750

755

760

765

770

775

780

785

790

795

800

805

810

815

815

820

825

830

835

840

845

850

855

860

865

870

875

880

885

890

895

900

905

910

915

920

925

930

935

940

945

950

955

960

965

970

975

980

985

990

995

1000

1005

1010

1015

1020

1025

1030

1035

1040

1045

1050

1055

1060

1065

1070

1075

1080

1085

1090

1095

1100

1105

1110

1115

1120

1125

1130

1135

1140

1145

1150

1155

1160

1165

1170

1175

1180

1185

1190

1195

1200

1205

1210

1215

1220

1225

1230

1235

1240

1245

1250

1255

1260

1265

1270

1275

1280

1285

1290

1295

1300

1305

1310

1315

1320

1325

1330

1335

1340

1345

1350

1355

1360

1365

1370

1375

1380

1385

1390

1395

1400

1405

1410

1415

1420

1425

1430

1435

1440

1445

1450

1455

1460

1465

1470

1475

1480

1485

1490

1495

1500

1505

1510

1515

1520

1525

1530

1535

1540

[0014] The antiviral agent of the present invention can be administered over a range of 1  $\mu$ g to 100 g of the effective ingredient per day. Moreover, the dose can be varied according to the body weight and symptom of a patient and other factors recognized by a person with ordinary skill in the art.

[0015] In addition, although the administration form of the antiviral agent of the present invention is not limited, the effective ingredient can be mixed with pharmaceutically acceptable binders, antiseptics, stabilizers, flavorings, salts and so forth in a unit dose form ordinary recognized as being required for pharmaceutical preparation. The amount of effective ingredient in these compositions or agents is suitably determined so as to obtain a suitable amount within the indicated range.

[0016] Although there are no particular restrictions on the administration route of the agent of the present invention, it can be administered by oral administration, inhalation, intracutaneous, subcutaneous, intramuscular or intravenous administration. As the forms of the agent of the present invention, tablets, liquids, capsules, inhalants and injection preparations are exemplified.

#### Examples

##### Example 1

Effect of 6-Amino-Purine (Referred to as Adenine hereinafter) on Selective Induction of Apoptosis to Virus Infected Cells

[0017] Adenine, a commercially available reagent, was dissolved in physiologically phosphate buffered saline, and added to the cell culture medium at the final concentrations shown in Fig. 1. Physiologically phosphate buffered saline was used as a control.

[0018]  $1.25 \times 10^5$  cells/ml of HIV-1 chronically infected cell line Molt-4 (abbreviated as Molt-4/HIV) as virus chronically infected cells, or  $1.25 \times 10^5$  cells/ml of Molt-4 cell line (abbreviated as Molt-4) as virus uninfected cells, were cultured for 5 days at 37°C under 5% CO<sub>2</sub> in RPMI-1640 cell culture medium containing 10% (V/V) of human type AB serum and penicillin/streptomycin. The number of viable cells was assayed on day 5 by trypan blue exclusion test. The Molt-4/HIV cells were also collected by centrifugation, and DNA fragments were extracted in accordance with routine methods and subjected to electrophoresis on agarose gel to detect a DNA ladder, for the purpose of detecting apoptotic cell death.

[0019] As shown in Fig. 1, adenine induced selective cell death to Molt-4/HIV cells. A clear DNA ladder was detected as shown in Fig. 4. It demonstrated that adenine had the activity of inducing selective apoptosis to HIV chronically infected cells.

##### Example 2

Effect of Guanosine 5'-Diphosphate (Referred to as GDP hereinafter) on Selective Induction of Apoptosis to Virus Infected Cells

[0020] GDP, a commercially available reagent, was dissolved in physiologically phosphate buffered saline, and added to the cell culture medium at the final concentrations shown in Fig. 2. Physiologically phosphate-buffered saline was used as a control.

[0021] In addition, cell culturing conditions, assay method and so forth were the same as those described in Example 1.

[0022] As shown in Fig. 2, GDP induced selective cell death to Molt-4/HIV cells and a DNA ladder was clearly detected as shown in Fig. 4. It demonstrated that GDP had the activity of inducing selective apoptosis to HIV chronically infected cells.

##### Example 3

Effect of Hypoxanthine 9- $\beta$ -D-Ribofuranoside (Referred to as Inosine hereinafter) on Selective Induction of Apoptosis to Virus Infected Cells

[0023] Inosine, a commercially available reagent, was dissolved in physiologically phosphate buffered saline, and added to the cell culture medium at the final concentrations shown in Fig. 3. Physiologically phosphate buffered saline was used as a control. In addition, cell culturing conditions, assay method and so forth were the same as those described in Example 1.

[0024] As shown in Fig. 3, inosine induced selective cell death to Molt-4/HIV cells and a DNA ladder was clearly detected as shown in Fig. 4. It demonstrated that inosine had the activity of inducing selective apoptosis to HIV chronically infected cells.

##### Claims

1. Use of one or more compounds selected from the group consisting of adenine, hypoxanthine, guanine, their water-soluble derivatives and their prodrugs in the preparation of an antiviral agent.
2. The use according to claim 1 wherein the compound is adenine.
3. The use according to claim 1 wherein the compound is inosine.
4. The use according to claim 1 wherein the compound is guanosine 5'-diphosphate.
5. The use according to any of the preceding claims wherein the antiviral agent is directed against the human immunodeficiency virus (HIV).

6. The use according to any of the preceding claims  
wherein the antiviral agent induces the selective  
apoptosis of infected cells.

5

10

15

20

25

30

35

40

45

50

55

Fig. 1




Fig. 2




Fig. 3





Fig. 4



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**